Eli LIlly's Zyprexa (olanzapine) and Symbyax (olanzapine/fluoxetine) have been updated to include stronger warnings due to the potential metabolic changes associated with the drugs.
The label changes include warnings for weight gain, hyperlipidemia and hyperglycemia. Also included is greater association between olanzipine and increases in glucose levels than with some other atypical antipsychotics.
"Today's communication is part of Lilly's historical and ongoing commitment to inform doctors and patients about updated prescribing information," said Sara Corya, M.D., the global medical director of Lilly. "Zyprexa is an important treatment option for patients suffering from the devastating effects of schizophrenia and bipolar disorder, as is Symbyax for patients with bipolar depression. This information will continue to help healthcare professionals evaluate and make the best treatment decisions for individual patients."
The New York Times reported that, as of January 2007, Lilly has spent $1.2 billion settling lawsuits from people that claim to have developed diabetes or heart problems after having taken Zyprexa.
[Source: MedPageToday]
» FDA Concerned Over Lilly's Zyprexa Adhera from PharmaGazette
The U. S. Food and Drug Adminstration stated today that it is concerned about excessive sedation following injections of Eli Lilly's long-acting form of its schizophrenia drug Zyprexa.While the drug was found to be effective for acute and long... [Read More]
Tracked on: February 4, 2008 3:30 PM | Permalink to Trackback